Market Cap : 7.03 B | Enterprise Value : 9.98 B | PE Ratio : 25.74 | PB Ratio : 2.10 |
---|
NAS:SYNH has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NAS:SYNH has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Debt-to-EBITDA measures a company's ability to pay off its debt.
Syneos Health's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2022 was $64 Mil. Syneos Health's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2022 was $3,043 Mil. Syneos Health's annualized EBITDA for the quarter that ended in Jun. 2022 was $732 Mil. Syneos Health's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2022 was 4.24.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's
The historical rank and industry rank for Syneos Health's Debt-to-EBITDA or its related term are showing as below:
During the past 11 years, the highest Debt-to-EBITDA Ratio of Syneos Health was 22.82. The lowest was 2.42. And the median was 6.14.
The historical data trend for Syneos Health's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Syneos Health's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Diagnostics & Research industry and Healthcare sector, Syneos Health's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Syneos Health's Debt-to-EBITDA falls into.
Debt-to-EBITDA measures a company's ability to pay off its debt.
Syneos Health's Debt-to-EBITDA for the fiscal year that ended in Dec. 2021 is calculated as
Debt-to-EBITDA | = | Total Debt | / | EBITDA | ||
= | (Short-Term Debt & Capital Lease Obligation | + | Long-Term Debt & Capital Lease Obligation) | / | EBITDA | |
= | (63.685 | + | 3015.7) | / | 630.037 | |
= | 4.89 |
Syneos Health's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2022 is calculated as
Debt-to-EBITDA | = | Total Debt | / | EBITDA | ||
= | (Short-Term Debt & Capital Lease Obligation | + | Long-Term Debt & Capital Lease Obligation) | / | EBITDA | |
= | (64.086 | + | 3043.214) | / | 732.028 | |
= | 4.24 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Jun. 2022) EBITDA data.
In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's
Thank you for viewing the detailed overview of Syneos Health's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Zulueta Alfonso G | director | LILLY CORPORATE CENTER INDIANAPOLIS IN 46285 |
Bodem Barbara W. | director | C/O DENTSPLY SIRONA INC 13320 BALLANTYNE CORPORATE PLACE CHARLOTTE NC 28277 |
Brooks Michael Lee | officer: See remarks | C/O SYNEOS HEALTH, INC. 1030 SYNC STREET MORRISVILLE NC 27560 |
Wilkes David S. | director | ONE BAXTER PARKWAY DEERFIELD IL 60015 |
Connaughton Bernadette | director | C/O VISTERRA, INC. ONE KENDALL SQUARE, #B3301 CAMBRIDGE MA 02139 |
Klitgaard William E | director | 210 CARNEGIE CENTER PRINCETON NJ 08540 |
Meyers Kenneth F | director | 275 NORTH FIELD DRIVE LAKE FOREST IL 60045 |
Monaghan Matthew E. | director | ONE INVACARE WAY ELYRIA OH 44035 |
Harty Linda S | director | MEDTRONIC PLC 710 MEDTRONIC PARKWAY NE, LC-150 MINNEAPOLIS MN 55432 |
Kralowetz Donna Hildebrand | officer: SVP, Chief Accounting Officer | C/O SYNEOS HEALTH, INC. 1030 SYNC STREET MORRISVILLE NC 27560 |
Colvin Paul | officer: Pres., Clinical Solutions | C/O SYNEOS HEALTH, INC. 1030 SYNC STREET MORRISVILLE NC 27560 |
Parks Robert | officer: EVP, Chief Accounting Officer | C/O SYNEOS HEALTH, INC. 1030 SYNC STREET MORRISVILLE NC 27560 |
Olefson Jonathan | officer: General Counsel & Corp Secty | C/O SYNEOS HEALTH, INC. 1030 SYNC STREET MORRISVILLE NC 27560 |
Meggs Jason M. | officer: Chief Financial Officer | C/O SYNEOS HEALTH, INC. 1030 SYNC STREET MORRISVILLE NC 27560 |
Gpe Vii Gp S.a.r.l. | 10 percent owner | CO ADVENT INTERNATIONAL 800 BOYLSTON STREET BOSTON MA 02199 |
From GuruFocus
By Marketwired 06-03-2021
By GuruFocusNews 12-21-2021
Other Sources
By Zacks 2022-03-29
By Zacks 2021-11-04
By Zacks 2021-11-03
By Zacks 2022-03-28
By Zacks 2021-11-23
By Zacks 2022-02-18
By Zacks 2021-09-10
By Zacks 2021-10-13
By Zacks 2022-03-10
By Zacks 2021-09-29
By Zacks 2022-03-18
By Seekingalpha 2021-11-03
By Zacks 2022-03-04
By Zacks 2021-08-10